Our customers' Feedback
Search:
Perform search
Categories list

Generic Symbicort

News
Symbicort
Symbicort photo

Generic Symbicort (Budesonide Formoterol)

Anti-inflammatories, Asthma

PackagePricePer ItemSavingsOrder
100mcg + 6mcg 120 dpi × 1 inhaler$34.95$34.95Add to cart
100mcg + 6mcg 120 dpi × 2 inhaler$59.95$29.98$9.95Add to cart

PackagePricePer ItemSavingsOrder
160mcg + 4.5mcg 60 dpi × 1 inhaler$69.95$69.95Add to cart
160mcg + 4.5mcg 60 dpi × 2 inhaler$129.95$64.97-Add to cart

PackagePricePer ItemSavingsOrder
200mcg + 6mcg 120 dpi × 1 inhaler$39.95$39.95Add to cart
200mcg + 6mcg 120 dpi × 2 inhaler$69.95$34.98$9.95Add to cart

PackagePricePer ItemSavingsOrder
400mcg + 6mcg 120 dpi × 1 inhaler$44.95$44.95Add to cart
400mcg + 6mcg 120 dpi × 2 inhaler$79.95$39.98$9.95Add to cart

Most popular quantity.
Temovate
$ 3.00
Generic Temovate
(Clobetasol 0.05% 15g)
Ventolin
$ 0.50
Generic Ventolin
(Albuterol (salbutamol) 2/4mg)
Ventolin Inhaler
$ 13.74
Generic Ventolin Inhaler
(Albuterol 100mcg 200dpi)
Volmax Cr
$ 0.51
Generic Volmax Cr
(Albuterol (salbutamol) 4/8mg)
Voltaren
$ 0.58
Generic Voltaren
(Diclofenac Sodium 50/100mg)
Xylocaine
$ 5.00
Generic Xylocaine
(Lidocaine 2% 30g)
Social bookmarks:
Articles
Choose your language:



Money backguarantee
Secureshopping

Our billing is certified by:

Secure shopping certificates

Special Offer!

  • Glaxo stokes triple-combo hopes with data topping AZ's Symbicort - FiercePharma

    FiercePharmaGlaxo stokes triple-combo hopes with data topping AZ's SymbicortFiercePharmaMonday, the company announced that the pipeline med had nailed both of its primary endpoints in a Phase III study, topping rival Symbicort from AstraZeneca on metrics measuring lung function and health-related quality of life.

  • Glaxo's triple combo COPD candidate beats AstraZeneca's Symbicort Turbohaler in late-stage study; regulatory filings ... - Seeking Alpha

    PMLiVEGlaxo's triple combo COPD candidate beats AstraZeneca's Symbicort Turbohaler in late-stage study; regulatory filings .

  • Triple Combination Therapy Shows Promise in COPD; Superior to Symbicort/Turbohaler Therapies - COPD News Today

    COPD News TodayTriple Combination Therapy Shows Promise in COPD; Superior to Symbicort/Turbohaler TherapiesCOPD News TodayFULFIL is a randomized, double-blind, multicenter study designed to evaluate the efficacy and safety of a daily dose of the FF/UMEC/IV triple therapy vs.

  • AstraZeneca's Growth Platform Includes Symbicort, Pulmicort - Market Realist

    Market RealistAstraZeneca's Growth Platform Includes Symbicort, PulmicortMarket RealistAstraZeneca's (AZN) respiratory, inflammation, and autoimmunity (or RI&A) segment is included in the company's growth platform and a key focus area for development.

  • Can GlaxoSmithKline plc (ADR) Subsist Advair's Patent Expiry - Business Finance News

    Business Finance NewsCan GlaxoSmithKline plc (ADR) Subsist Advair's Patent ExpiryBusiness Finance NewsThe main competitor of GSK's respiratory franchise is AstraZeneca's plc (ADR) (NYSE:AZN) Symbicort.

    Copyright © cheapgenerics24.com